pancreatic cancer

envie a um amigo share this

Cambridge Pancreatic Cancer Symposium

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

 

05 May, 2017

 

See more informations here: http://www.cambridge-pcc.org/upcoming_events.html

Cambridge Pancreatic Cancer Symposium

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

 

05 May, 2017

 

See more informations here: http://www.cambridge-pcc.org/upcoming_events.html

The International Symposium on Pancreatic Cancer 2016

Bute Hall at the University of Glasgow, Scotland, United Kingdom

 

09 - 12 June, 2016

 

See more informations here: http://pancreas2016.org/

The International Symposium on Pancreatic Cancer 2016

Bute Hall at the University of Glasgow, Scotland, United Kingdom

 

09 - 12 June, 2016

 

See more informations here: http://pancreas2016.org/

The International Symposium on Pancreatic Cancer 2016

Bute Hall at the University of Glasgow, Scotland, United Kingdom

 

09 - 12 June, 2016

 

See more informations here: http://pancreas2016.org/

The International Symposium on Pancreatic Cancer 2016

Bute Hall at the University of Glasgow, Scotland, United Kingdom

 

09 - 12 June, 2016

 

See more informations here: http://pancreas2016.org/

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer

O adenocarcinoma do pâncreas (ACP) é uma neoplasia altamente agressiva, com um carácter acentuadamente invasivo e um perfil de expressão de microRNAs anormal, que tem sido associado às propriedades malignas desta doença. A falta de tratamentos eficazes para o ACP levou-nos a considerar a possibilidade de usar os microRNAs, como potenciais alvos terapêuticos, no desenvolvimento de uma estratégia de terapia génica com relevância clinica para esta doença.

MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer

O adenocarcinoma do pâncreas (ACP) é uma neoplasia altamente agressiva, com um carácter acentuadamente invasivo e um perfil de expressão de microRNAs anormal, que tem sido associado às propriedades malignas desta doença. A falta de tratamentos eficazes para o ACP levou-nos a considerar a possibilidade de usar os microRNAs, como potenciais alvos terapêuticos, no desenvolvimento de uma estratégia de terapia génica com relevância clinica para esta doença.

Treating pancreatic cancer and prostate cancer with gold nanoparticles

A multidisciplinary team of University of Porto - researchers from the Laboratório de Engenharia de Processos Ambiente e Energia  (LEPAE) of FEUP, the IBMC and IPATIMUP - together with researchers from Chalmers University of Technology (Sweden), the University of Nebraska Medical Center (USA) and Institute for Cancer Research (Norway) studied, for three years, the use of gold nanoparticles as a way to treat cancer and concluded that they increase efficiency permeation of retention and penetrability of therapeutic drugs in tissue affected by the disease.